• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices

AstraZeneca

New CEO and CFO take over at bone-cutting robot maker AOT

March 31, 2022 By Jim Hammerand

Advanced Osteotomy Tools (AOT) announced that Elmar Zurbriggen will become CEO and Peter Oprandi will become CFO effective tomorrow. Basel, Switzerland-based AOT developed the world’s first certified surgical device to cut bone with a laser. The system is called CARLO, for Cold Ablation Robot-guided Laser Osteotome.  “Elmar and Peter have both gained decades of experience as […]

Filed Under: Blog, Business/Financial News, News Well, Surgical, Surgical Robotics Tagged With: Advanced Osteotomy Tools, AstraZeneca, DePuy Synthes, Johnson & Johnson, Lonza

10 of the best pharma companies to work for

May 26, 2021 By Brian Buntz

The pharmaceutical industry is on the upswing and is poised to have a compound annual growth rate of 13.7% from 2020 to 2027, according to projections from Grand View Research. The industry’s resurgence is a good opportunity for employees in the sector, who frequently enjoy comfortable salaries. To get a sense of which pharmaceutical companies […]

Filed Under: Featured, Pharmaceutical Tagged With: AstraZeneca, Biogen, Eisai, Janssen, Johnson & Johnson, Merck, Moderna, Novartis, Pfizer, Roche, Roche Pharmaceuticals, Sage Therapeutics

Pharma’s top 20 R&D spenders in 2020

May 13, 2021 By Brian Buntz

The past year has been an unprecedented time for the pharmaceutical industry. On the one hand, the pandemic resulted in substantial delays to clinical trials while also forcing sponsors to rethink clinical trial design to protect participants. But on the other hand, the pandemic underscored the importance of the pharma industry in society.  While the […]

Filed Under: Featured, Pharmaceutical, Research & Development Tagged With: AstraZeneca, Biogen, Boehringer Ingelheim, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Eli Lilly, H. Lundbeck, Incyte, Janssen, Merck, Novartis, Otsuka Holdings, Pfizer, Regeneron Pharmaceuticals, Roche, Roche Group, Roche Pharmaceuticals, Sumitomo Danippon Pharma, UCB, Vertex Pharmaceuticals

Pharma 50: Here’s how the world’s largest pharma companies are doing

May 12, 2021 By Chris Newmarker

The global pharmaceutical industry held up well during the pandemic, with 10 of the largest businesses only seeing a roughly –3% drop in revenue in 2020. Eight of the 10 even came out ahead. That’s one of the big takeaways from our sister publication Drug Discovery & Development’s inaugural Pharma 50, a compilation of data […]

Filed Under: Business/Financial News, Featured, Pharmaceutical Tagged With: AstraZeneca, Gilead Sciences, GlaxoSmithKline plc, Janssen Pharmaceuticals, Johnson & Johnson, Merck, Novartis, Pfizer, Pharma 50, Roche, Sanofi, Sinopharm

U.S. to donate 60M doses of AstraZeneca’s COVID-19 vaccine

April 26, 2021 By Sean Whooley

The Biden administration announced today that it will begin sharing its store of AstraZeneca’s COVID-19 vaccine following safety reviews. Once the vaccine clears federal safety reviews, 60 million doses of the vaccine are expected to be made available, according to a Tweet from senior White House advisor Andy Slavitt. “BREAKING: U.S. to release 60 million Astra Zeneca […]

Filed Under: Business/Financial News, Contract Manufacturing, Featured, Pharmaceutical Tagged With: AstraZeneca, coronavirus, COVID-19, COVID-19 vaccine, Joe Biden

FDA releases scathing inspection report regarding Emergent BioSolutions plant

April 21, 2021 By Brian Buntz

An FDA report cites multiple failures in an Emergent BioSolutions plant tapped to produce vaccines for Johnson & Johnson and AstraZeneca. The vaccine plant had been forced to discard up to 15 million doses of Johnson & Johnson’s COVID-19 vaccine in a single manufacturing batch. Emergent Biosolutions recently paused production of the vaccine during the FDA inspection and […]

Filed Under: Featured, Pharmaceutical Tagged With: AstraZeneca, AstraZeneca plc, coronavirus, COVID-19 vaccine, COVID-19 vaccines, Emergent BioSolutions, FDA, Johnson and Johnson

A quick history of the tech behind J&J, AstraZeneca’s COVID-19 vaccines

April 16, 2021 By Brian Buntz

Regulatory authorities in the U.S. and Europe have either paused or constrained the use of COVID-19 vaccines from AstraZeneca (LON:AZN) and Johnson & Johnson (NYSE:JNJ), causing some to wonder why the adenoviral-vector vaccines have been potentially linked to similar blood clotting events. Researchers have observed blood clotting events associated with adenoviral vectors since the late-1990s […]

Filed Under: Featured, Pharmaceutical Tagged With: adenovirus vector, AstraZeneca, coronavirus, COVID-19, Johnson & Johnson

EU won’t renew J&J, AstraZeneca vaccine contracts, report says

April 14, 2021 By Sean Whooley

Reports from Italy claim that the European Union Commission won’t renew COVID-19 vaccine contracts next year with AstraZeneca and Johnson & Johnson. According to Reuters, Italian outlet La Stampa reported that sources from the Italian health ministry have said the commission does not want to pursue contract renewals with those two companies once those encompassing the current year expire, […]

Filed Under: Business/Financial News, Contract Manufacturing, Featured, Pharmaceutical Tagged With: AstraZeneca, BioNTech, coronavirus, COVID-19, COVID-19 vaccine, COVID-19 vaccines, Johnson & Johnson, Moderna, Pfizer

EMA begins investigation of J&J COVID-19 vaccine’s blood clotting potential

April 9, 2021 By Brian Buntz

The European Medicines Agency (EMA) announced that it is beginning a review of blood clots appearing in a handful of recipients of the Johnson & Johnson COVID-19 vaccine.  EMA recently concluded that blood clots associated with low blood platelet levels were a “very rare” side effect of Vaxzevria, the vaccine from AstraZeneca.  Four recipients of […]

Filed Under: Featured, Pharmaceutical Tagged With: AstraZeneca, Clinical Trials, coronavirus, COVID-19, COVID-19 vaccines, Johnson and Johnson

AstraZeneca vaccine linked to rare blood clots, according to EMA official 

April 6, 2021 By Brian Buntz

European Medicines Agency (EMA) official Marco Cavaleri said there was a link between AstraZeneca’s COVID-19 vaccine and rare reports of blood clots, including pulmonary embolism, deep vein thrombosis and thrombocytopenia, according to a Reuters report. Two separate research groups in Europe had reached similar conclusions regarding the blood clots in March. Get the full story from our sister […]

Filed Under: Featured, Pharmaceutical Tagged With: AstraZeneca, AstraZeneca plc, blood clots, coronavirus, COVID-19

NIAID expresses concern over AstraZeneca’s COVID-19 vaccine data

March 23, 2021 By Sean Whooley

The National Institute of Allergy and Infectious Diseases (NIAID) has announced concerns with data from AstraZeneca’s COVID-19 vaccine trial. NIAID, a wing of the National Institutes of Health (NIH), said in a statement today that it was concerned that information the company released from its AZD1222 vaccine clinical trial may be outdated. In turn, that […]

Filed Under: Clinical Trials, Featured, Pharmaceutical, Regulatory/Compliance Tagged With: AstraZeneca, coronavirus, COVID-19, COVID-19 vaccine, COVID-19 vaccine trial, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH)

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy